Details for Patent: 10,597,377

Which drugs does patent 10,597,377 protect, and when does it expire?

Patent 10,597,377 protects PALSONIFY and is included in one NDA.

This patent has thirty-four patent family members in twenty-five countries.

Summary for Patent: 10,597,377

Title:	Somatostatin modulators and uses thereof
Abstract:	Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Inventor(s):	Jian Zhao, Shimiao Wang, Yunfei ZHU
Assignee:	Crinetics Pharmaceuticals Inc
Application Number:	US16/407,031
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,597,377

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Crinetics	PALSONIFY	paltusotine hydrochloride	TABLET;ORAL	219070-001	Sep 25, 2025		RX	Yes	No	10,597,377		Y	Y		TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
Crinetics	PALSONIFY	paltusotine hydrochloride	TABLET;ORAL	219070-002	Sep 25, 2025		RX	Yes	Yes	10,597,377		Y	Y		TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION

International Family Members for US Patent 10,597,377

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017296392
Australia	2020277122
Brazil	112019000692
Canada	3030423
China	109715612